20-Year Pro Trader Reveals His "MoneyLine"
Ditch your indicators and use the "MoneyLine". A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.
- SAB Biotherapeutics (NASDAQ:SABS) will discontinue its work with the U.S. Department of Defense (DoD) under a prototype research and development agreement.
- The agreement, awarded in 2019, underwent significant modifications due to the COVID-19 pandemic, and the government's evolving requirements no longer align with the agreement's goals as initially contemplated.
- As part of the closeout process, SAB and the DoD will negotiate comprehensively to address all open items under the agreement, which is expected to include a multi-million-dollar payment to SAB.
- Also Read: NIH Discontinues COVID-19 Phase 3 Trial Assessing SAB Biotherapeutics' SAB-185.
- The conclusion of SAB's agreement with the DoD will allow the company to focus on its core priorities and expand its current pipeline.
- SAB has advanced its preclinical program, SAB-195, a polyclonal antibody treatment for Clostridioides difficile Infection, a potentially terminal gastrointestinal infectious disease.
- SAB expects to file an IND within 18 months and announce topline results, including an indication of biological activity, from a Phase 1 trial in 2024.
- Price Action: SABS shares closed at $1.15 on Tuesday.
20-Year Pro Trader Reveals His "MoneyLine"
Ditch your indicators and use the "MoneyLine". A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!